BR100 Decreased By (-0.25%)
BR30 Decreased By (-0.64%)
KSE100 Decreased By (-0.41%)
KSE30 Decreased By (-0.67%)
BECO 5.83 Decreased By ▼ -0.20 (-3.32%)
BML 57.90 Increased By ▲ 5.15 (9.76%)
BOP 33.79 Decreased By ▼ -0.46 (-1.34%)
CNERGY 8.15 Decreased By ▼ -0.01 (-0.12%)
DCL 11.79 Decreased By ▼ -0.55 (-4.46%)
FCCL 53.49 Decreased By ▼ -0.40 (-0.74%)
FCSC 5.40 Increased By ▲ 0.18 (3.45%)
FFL 17.84 Decreased By ▼ -0.19 (-1.05%)
FNEL 1.30 No Change ▼ 0.00 (0%)
HUMNL 11.11 Increased By ▲ 0.11 (1%)
KEL 8.02 Decreased By ▼ -0.09 (-1.11%)
KOSM 5.45 Increased By ▲ 0.07 (1.3%)
MLCF 87.40 Decreased By ▼ -0.65 (-0.74%)
NBP 184.24 Decreased By ▼ -2.24 (-1.2%)
PACE 11.62 Increased By ▲ 0.90 (8.4%)
PAEL 40.25 Increased By ▲ 0.31 (0.78%)
PIAHCLA 26.12 Decreased By ▼ -0.05 (-0.19%)
PIBTL 17.14 Decreased By ▼ -0.18 (-1.04%)
PPL 228.73 Decreased By ▼ -4.05 (-1.74%)
PRL 34.49 Decreased By ▼ -0.46 (-1.32%)
PTC 67.54 Decreased By ▼ -0.02 (-0.03%)
SEARL 90.93 No Change ▼ 0.00 (0%)
SSGC 26.83 Decreased By ▼ -0.34 (-1.25%)
TELE 8.53 Decreased By ▼ -0.04 (-0.47%)
THCCL 66.14 Increased By ▲ 6.01 (10%)
TPLP 9.33 Increased By ▲ 0.57 (6.51%)
TREET 24.51 Decreased By ▼ -0.03 (-0.12%)
TRG 71.61 Decreased By ▼ -0.14 (-0.2%)
WAVES 10.98 Increased By ▲ 1.00 (10.02%)
WTL 1.28 Increased By ▲ 0.02 (1.59%)
World

Greece to claim back money in Novartis corruption case: PM

Published February 12, 2018 Updated February 12, 2018 03:50pm

ATHENS: Greece will claim billions of euros from Swiss pharmaceutical giant Novartis, Prime Minister Alexis Tsipras said Monday as he called on parliament to investigate bribes allegedly paid to prominent politicians.

"The government will not give up the claim to funds of which Novartis deprived the Greek people," Tsipras said.

"We will make use of every power afforded by national and international law to recover the money stolen from the Greek people, down to the last euro," he told his party lawmakers.

Investigators believe that Novartis overcharged the Greek state for medicines in collaboration with government officials who received kickbacks, bilking taxpayers to the tune of three billion euros ($3.7 billion) between 2006 and 2015.

Overall, similar practises across the health sector are believed to have cost Greece some 23 billion euros between 2000 and 2015.

Novartis on Monday said it has been cooperating with US and Greek authorities for over 14 months, whilst conducting an internal audit of its own and pledging to take action against errant staff.

"We pledge to act accordingly on possible actions that do not meet our high moral standards of business," it said.

The company said it was not fully aware of the case dossier, but argued that "public debate surrounding the case includes inaccuracies and conjecture".

Two former Greek prime ministers and eight former ministers have been named by protected witnesses -- whose identity is being withheld -- as allegedly being involved in approving overpriced Novartis contracts in return for kickbacks.

Only parliament has the power to investigate former ministers for actions taken during their term in office. The chamber is expected to approve Tsipras' demand for a parliamentary commission to look into the case.

Several of the politicians allegedly named, including former prime minister Antonis Samaras and ex-health minister Dimitris Avramopoulos -- now the EU's migration chief -- have denied involvement and called on the witnesses to publicly reveal themselves.

Greece's Justice Minister Stavros Kontonis last year said Novartis had likely bribed "thousands" of doctors and civil servants to promote its products.

He also accused Novartis of continuing to sell "overpriced" drugs even after the country was plunged into economic crisis in 2010 and huge cuts were imposed on state budgets, leaving many Greeks without access to affordable medicine.

The case gained attention following a suicide attempt by a Novartis manager in Athens in January 2017.

Novartis was investigated by US authorities in 2014, accused of paying bribes in order to boost sales of some of its medicines, and was later fined $390 million by the US Justice Department.

In March 2017, Novartis also paid $25 million to settle claims involving its Chinese subsidiary.

 

 

Copyright AFP (Agence France-Press), 2018
 

 

Comments

Comments are closed for this article.